An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A or B Patients With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis

Pfizer Inc.0 个研究点目标入组 145 人开始时间: 2020年3月10日最近更新: 2021年7月26日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Pfizer Inc.
入组人数: 145

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Male

入选标准

•Participants are eligible to be included in the study only if all of the
•following criteria apply:
•1. Participant must be male and 12 to <75 years of age with a minimum
•body weight of 35 kg at the time of signing the informed consent.
•Type of Participant and Disease Characteristics
•2. Participants with a diagnosis of severe hemophilia A or B (FVIII or FIX
•activity <1%, respectively) documented by a clinical laboratory prior to
•Enrollment. The severity of hemophilia may be confirmed either by
•documented historical evidence from a clinical laboratory prior to
•Screening or by factor activity obtained from a clinical laboratory (which
•may include the central laboratory for this study) prior to Enrollment.
•3. Participants who are enrolled into the Non-Inhibitor Cohort must also
•meet the following criteria:
•No detectable or documented history of inhibitors (=0.6 BU/mL or
•greater than the upper limit of normal [ULN] for the testing laboratory)
•against FVIII or FIX prior to enrollment (Baseline of Observational
•Participants receiving routine prophylaxis (defined as treatment by IV
•injection of factor concentrate to prevent bleeding) treatment with FVIII/FIX replacement, have demonstrated at least 80% compliance
•with scheduled prophylaxis regimen during 6 months prior to
•enrollment, and willing to continue to receive routine prophylaxis
•treatment with FVIII/FIX replacement during the Observational Phase.
•Participants with on-demand treatment regimen with =6 acute
•bleeding episodes (spontaneous or traumatic) that required coagulation
•factor infusion during the 6 months period prior to Enrollment into
•Observational Phase and willing to continue to receive on demand
•treatment during the Observational Phase. Surgical bleeding episodes
•do not apply to this criterion.
•4. Participants who are enrolled into the Inhibitor Cohort must also meet
•the following criteria:
•Documentation of current high titer inhibitor (=5 BU/mL); or current
•low titer inhibitor (<5 BU/mL) refractory to FVIII or FIX replacement
•and with FVIII or FIX recovery <60% of expected within previous 6
•months prior to Enrollment into Observational Phase.
•Participants who have documented inhibitors while on factorreplacement
•therapy but who do not meet the quantitative inhibitor
•criteria described in the prior bullet at the time of Screening (eg,
•participant with a previously documented high-titer inhibitor (=5
•BU/mL) and whose condition precludes re-challenge with FVIII or FIX
•replacement) may be considered for eligibility on a case-by-case basis
•with discussion and endorsement from the Pfizer Medical Monitor.
•Participants with on-demand treatment regimen with =6 bleeding
•episodes (spontaneous or traumatic) necessitating treatment with
•bypass factor during the 6 months prior to Enrollment into Observational
•Phase and willing to continue to receive on-demand treatment during
•the Observational Phase. Surgical bleeding episodes do not apply to this
•Informed Consent
•6. Participant or legally authorized representative, or participant's
•caregiver capable of giving signed informed consent (or minor assent,
•when applicable) as described in Appendix 1 which includes compliance
•with the requirements and restrictions listed in the informed consent
另有 5 项未显示

排除标准

•Participants are excluded from the study if any of the following criteria apply:
•Medical Conditions
•1. Previous or current treatment for or history of coronary artery
•diseases, venous or arterial thrombosis (Common Terminology Criteria
•for Adverse Events [CTCAE] Grade >1), or ischemic disease (except
•treatment for catheter associated thrombosis).
•2. Known planned surgical procedure during the planned study period.
•3. Known hemostatic defect other than hemophilia A or B.
•4. Abnormal renal or hepatic function as defined by the following
•laboratory results at Screening:
•a. Alanine transaminase (ALT) >2 × upper limit of normal (ULN)
•b. Bilirubin >1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if
•bilirubin is fractionated and direct bilirubin <35%)
•c. Current unstable liver or biliary disease per investigator assessment
•defined by the presence of ascites, encephalopathy, coagulopathy,
•hypoalbuminaemia, oesophageal or gastric varices, persistent jaundice,
•or cirrhosis. NOTE: Stable chronic liver disease (including Gilbert's syndrome, asymptomatic gallstones, and chronic stable hepatitis B or C -
•eg, presence of hepatitis B surface antigen [HBsAg] or positive hepatitis
•C antibody test result at screening or within 3 months prior to starting
•study intervention) is acceptable if the participant otherwise meets
•entry criteria
•d. Serum albumin less than the lower limit of normal (LLN).
•e. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 (see
•Appendix 10.2.1 for formulas used in eGFR calculation).
•5. Abnormal hematology values as defined by the following laboratory
•tests at Screening:
•a. Platelet count <100,000/uL
•b. Hemoglobin level <10 g/dL
•6. Other acute or chronic medical or psychiatric condition including
•recent (within the past year) or active suicidal ideation or behavior or
•laboratory abnormality that may increase the risk associated with study
•participation or investigational product administration or may interfere
•with the interpretation of study results and, in the judgment of the
•investigator, would make the participant inappropriate for entry into this
•7. QTc >450 msec for male participants or QTc >480 msec in participants
•with bundle branch block.
•8. Individuals with hypersensitivity or an allergic reaction to hamster
•protein or other components of the study intervention.
•Prior/Concomitant Therapy
•9. Current routine prophylaxis with bypassing agent (eg, aPCC, BYCLOT,
•Prothrombin Complex Concentrates [PCC], or rFVIIa), non-coagulation
•non-factor replacement therapy (eg, emicizumab), or any previous
•treatment with a gene therapy product for treatment of hemophilia.
•Potential participants who have previously received investigational
•non-factor-based hemophilia therapy (eg, fitusiran) will be considered
•on a case-by-case basis, only after discussion and agreement between
•the investigator and the Pfizer Medical Monitor.
•10. Regular, concomitant therapy with immunomodulatory drugs (eg, IV
•immunoglobulin [IVIG], and routine systemic corticosteroids,
•rituximab).
另有 8 项未显示

研究者

发起方

Pfizer Inc.

相似试验

进行中（未招募）

1 期

PROPHYLAXIS STUDY OF PF-06741086 IN ADOLESCENT AND ADULT HEMOPHILIA PATIENTS WITH OR WITHOUT INHIBITORSHemophilia A or BMedDRA version: 20.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10060612Term: Hemophilia ASystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 100000004850

EUCTR2018-003660-31-HRPfizer Inc., 235 East 42nd Street, New York, NY 10017145

进行中（未招募）

1 期

PROPHYLAXIS STUDY OF PF-06741086 IN ADOLESCENT AND ADULT HEMOPHILIA PATIENTS WITH OR WITHOUT INHIBITORS

EUCTR2018-003660-31-FRPfizer Inc., 235 East 42nd Street, New York, NY 10017106

进行中（未招募）

1 期

EUCTR2018-003660-31-DEPfizer Inc.145

进行中（未招募）

1 期

PROPHYLAXIS STUDY OF PF-06741086 IN ADOLESCENT AND ADULT HEMOPHILIA PARTICIPANTS WITH OR WITHOUT INHIBITORS

EUCTR2018-003660-31-BGPfizer Inc.174

进行中（未招募）

1 期

EUCTR2018-003660-31-ESPfizer Inc., 235 East 42nd Street, New York, NY 10017106